S&P 500
5.481,24 +49,64 (+0,91%) Nasdaq
17.904,21 +215,33 (+1,22%) NIKKEI 225
38.102,44 -712,12 (-1,83%) Dólar/Euro
1,0739 +0,0030 (+0,28%) Petróleo Brent
84,38 +1,76 (+2,13%) Bitcoin EUR
62.421,49 +441,45 (+0,71%)
Nanjing Hicin Pharmaceutical Co., Ltd. (300584.SZ)
Nanjing Hicin Pharmaceutical Co., Ltd.
No.1 Hengfa Road
Economic and Technological Development Zone
Nanjing 210046
China
86 25 8322 2911
https://www.hicin.cn/page1/index1
Sector(es): Healthcare
Sector: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 553
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Yuping Cao | GM & Chairman of the Board | N/A | N/A | 1964 |
| Mr. Li Qun Wang | Secretary & Deputy GM | N/A | N/A | 1988 |
| Mr. Weicheng Liu | Deputy General Manager | N/A | N/A | 1981 |
Descripción
Nanjing Hicin Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals, pharmaceutical preparations, and synthetic chemicals in China. It offers antivirals, antibiotics, endocrine drugs, gastrointestinal drugs, orthopedic drugs, drugs for cardio-cerebral system, and immuno-modulate agents. The company also provides technical transferring services. In addition, it offers supply chain management services. The company also exports APIs; omeprazole sodium and cefepime hydrochloride for injections; and lansoprazole tablets to South-Asian countries, South-American countries, and European countries. Nanjing Hicin Pharmaceutical Co., Ltd. was founded in 2003 and is headquartered in Nanjing, China.
Gobierno corporativo
El ISS Governance QualityScore de Nanjing Hicin Pharmaceutical Co., Ltd., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
